Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Sofinnova Investments Inc.

Sofinnova Investments Inc. boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 46.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 553,095 shares of the specialty pharmaceutical company’s stock after purchasing an additional 176,029 shares during the quarter. Sofinnova Investments Inc. owned approximately 0.96% of Supernus Pharmaceuticals worth $27,489,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Torren Management LLC acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at $49,000. Hantz Financial Services Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 73.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 458 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 268 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Supernus Pharmaceuticals by 532.4% during the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock valued at $70,000 after acquiring an additional 1,182 shares during the period. Finally, Vestcor Inc acquired a new position in shares of Supernus Pharmaceuticals during the third quarter valued at $67,000.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 7,250 shares of the company’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total value of $359,600.00. Following the completion of the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. This represents a 29.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.50% of the company’s stock.

Supernus Pharmaceuticals Trading Down 1.2%

Shares of NASDAQ SUPN opened at $43.86 on Tuesday. Supernus Pharmaceuticals, Inc. has a twelve month low of $30.83 and a twelve month high of $59.68. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of -86.00, a PEG ratio of 0.95 and a beta of 0.55. The firm has a 50-day moving average of $48.55 and a two-hundred day moving average of $49.55.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SUPN shares. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Supernus Pharmaceuticals has an average rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.